PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Tang, Kun
Jiang, Kehua
Zhou, Hui
Liu, Haoran
Ye, Zhangqun
Xu, Hua
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP78-09
引用
收藏
页码：E1040 / E1040
页数：1
相关论文
共 50 条
  • [41] Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
    Kim, Jong Yeob
    Lee, Keum Hwa
    Kang, Jeonghyun
    Borcoman, Edith
    Saada-Bouzid, Esma
    Kronbichler, Andreas
    Hong, Sung Hwi
    Machado de Rezende, Leandro Fornias
    Ogino, Shuji
    Keum, Nana
    Song, Mingyang
    Luchini, Claudio
    van der Vliet, Hans J.
    Shin, Jae Il
    Gamerith, Gabriele
    CANCERS, 2019, 11 (11)
  • [42] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [43] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [44] Evaluating PD-L1 in Cytology to Determine Eligibility for Anti-PD-1/PD-L1 Immunotherapy in Patients with Head and Neck Squamous Cell Carcinoma
    Liu, Zhonghua
    Roy-Chowdhuri, Sinchita
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 246 - 247
  • [45] Evaluating PD-L1 in Cytology to Determine Eligibility for Anti-PD-1/PD-L1 Immunotherapy in Patients with Head and Neck Squamous Cell Carcinoma
    Liu, Zhonghua
    Roy-Chowdhuri, Sinchita
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 246 - 247
  • [46] Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
    de Jong, Florus C.
    Rutten, Vera C.
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [47] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [48] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [49] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [50] Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review
    An, Rui
    Zhao, Feng
    Wang, Liqian
    Shan, Jikang
    Wang, Xianjun
    BMJ OPEN, 2021, 11 (12):
12345